Stock Events

Stock Events

Insulet 

€254.2
89
+€6.1+2.46% Wednesday 15:54

Statistics

Day High
254.2
Day Low
248.1
52W High
290.5
52W Low
246.7
Volume
4
Avg. Volume
1
Mkt Cap
17.88B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18FebExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
0.7
0.88
1.06
1.23
Expected EPS
1.23441807492
Actual EPS
N/A

Financials

20.21%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
3.93BRevenue
794.72MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1PODD.MI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Tandem Diabetes Care
TNDM
Mkt Cap945.97M
Tandem Diabetes Care, Inc. competes directly with Insulet by offering insulin pump therapy for diabetes management, which is a direct alternative to Insulet's Omnipod system.
Medtronic
MDT
Mkt Cap116.33B
Medtronic plc is a major competitor in the insulin pump market, offering a range of products that compete with Insulet's offerings for diabetes management.
Dexcom
DXCM
Mkt Cap22.71B
DexCom, Inc. provides continuous glucose monitoring (CGM) systems that are often used in conjunction with insulin pumps like those offered by Insulet, making them a competitor in the broader diabetes management space.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories offers the FreeStyle Libre, a CGM system that competes with the integrated diabetes management solutions provided by Insulet.
Insulet
PODD
Mkt Cap22.03B
Insulet Corporation is listed as its own competitor due to an error. Please disregard this entry.
Senseonics
SENS
Mkt Cap287.64M
Senseonics Holdings, Inc. offers the Eversense CGM system, which competes in the diabetes management market by providing an alternative to the CGM solutions that can be used with Insulet's products.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk A/S is a leading provider of insulin and other diabetes care products that, while not a direct competitor in the insulin pump market, competes in the broader diabetes management space.
Sanofi
SNY
Mkt Cap124.45B
Sanofi provides a range of diabetes care solutions, including insulin therapies that compete with the insulin management solutions offered by Insulet.
Mannkind
MNKD
Mkt Cap1.72B
MannKind Corporation offers Afrezza, an inhaled insulin, providing a non-injectable alternative to insulin delivery that competes with traditional pump therapies like those offered by Insulet.

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Show more...
CEO
Dr. James R. Hollingshead Ph.D.
Employees
2300
Country
United States
ISIN
US45784P1012

Listings

MI
IT
1PODD.MI
LSE
GB
0ADR.LSE
MX
MX
PODD.MX
F
DE
GOV.F

0 Comments

Share your thoughts

FAQ

What is Insulet stock price today?▼
The current price of 1PODD.MI is €254.2 EUR — it has increased by +2.46% in the past 24 hours. Watch Insulet stock price performance more closely on the chart.
What is Insulet stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Insulet stocks are traded under the ticker 1PODD.MI.
What is Insulet market cap?▼
Today Insulet has the market capitalization of 17.88B
When is the next Insulet earnings date?▼
Insulet is going to release the next earnings report on February 18, 2026.
What were Insulet earnings last quarter?▼
1PODD.MI earnings for the last quarter are 1.07 EUR per share, whereas the estimation was 0.99 EUR resulting in a +8.75% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Insulet revenue for the last year?▼
Insulet revenue for the last year amounts to 3.93B EUR.
What is Insulet net income for the last year?▼
1PODD.MI net income for the last year is 794.72M EUR.
How many employees does Insulet have?▼
As of February 02, 2026, the company has 2,300 employees.
In which sector is Insulet located?▼
Insulet operates in the Healthcare sector.
When did Insulet complete a stock split?▼
Insulet has not had any recent stock splits.
Where is Insulet headquartered?▼
Insulet is headquartered in Acton, United States.